Slide 1: Fourth Quarter 2025 Earnings
Click Here to Edit Title Fourth Quarter 2025 Earnings February 4, 2026
Slide 2: Cautionary Statement
Cautionary Click Here to Statement Edit Title Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements ma
Slide 3: The Purposeful Evolution of IDEX
The Purposeful Evolution of IDEX $3.5B 2 0 2 5 R E V E N U E S Staging sustainable value creation in Phase III PHASE III P AT H T O H I G H E R GROWTH WITH 8020 1) Targeting higher-growth, advantaged markets PHASE II 2) Accelerating commercial OPTIMIZED WITH 8020 and operational business PHASE I Int
Slide 4: Building Momentum Across Health & Science Technologies
Building Momentum Across Health & Science Technologies Performance Materials Science Mott Diversified Life Sciences Pneumatics Solutions Industrials Differentiated air and Portfolio of applied Engineered porous Broad toolkit for High performance gas-moving products materials forming metal filtration
Slide 5: 4Q25 Highlights
IDEX 4Q25toHighlights Click Here Edit Title Delivered better than expected results despite macro uncertainty; leveraging 8020, Phase III growth strategies gaining traction HST logged record orders fueled by advantaged markets and increased demand in data center applications Industrial businesses rem
Slide 6: 4Q & FY 2025 Financial Performance
4Q & Here Click FY 2025 Financial to Edit Title Performance ($ in millions excl. EPS) Sales Adjusted Earnings per Share* +1% Organic* +1% Organic* +3% y/y +1% y/y $ 3,458 $7.95 $ 899 $ 3,269 $2.10 $2.04 $7.89 $ 863 4Q24 4Q25 2024 2025 4Q24 4Q25 2024 2025 Adjusted EBITDA Margin Free Cash Flow Convers
Slide 7: 4Q & FY 2025: Health & Science Technologies
4Q & FY Click 2025: Here Health to Edit Title & Science Technologies ($ in millions) Performance Highlights Orders Sales Adj. EBITDA Margin • 4Q Y/Y organic orders and sales growth driven by advantaged markets, led by AI-driven +34% Organic* +12% Organic* +5% Organic* +4% Organic* +60 bps y/y (10) b
Slide 8: 4Q & FY 2025: Fluid & Metering Technologies
4Q & FY Click 2025: Here Fluid to Edit & Metering Technologies Title ($ in millions) Performance Highlights Orders Sales Adj. EBITDA Margin • 4Q Y/Y organic orders driven by (20) bps y/y +30 bps y/y municipal water, positive price, and timing +4% Organic* +4% Organic* +1% Organic* Flat Organic* $ 1,
Slide 9: 4Q & FY 2025: Fire / Safety / Diversified Products
4Q & FY Click 2025: Here FireTitle to Edit & Safety / Diversified Products ($ in millions) Performance Highlights Orders Sales Adj. EBITDA Margin • Flat 4Q Y/Y organic orders reflect netting +50 bps y/y (10) bps y/y customer spend hesitancy in Dispensing, Flat Organic* Flat Organic* (5%) Organic* (1
Slide 10: Capital Deployment
Capital Deployment Maintaining a balance and returns-oriented approach Gross Leverage* Capital Deployment (Last 2 Years) IDEX Capital Deployment Framework ($ in millions) Maintain investment grade Maintain strong credit rating balance sheet $1,255 Gross leverage target < 2.0x 2.2x $205 80s foc
Slide 11: 2026 Guidance
2026 Guidance Click Here to EditSummary Title FY26 1Q26 Organic* Revenue Growth y/y 1% - 2% ~1% Adjusted EBITDA Margin* 26.5% - 27.0% ~24.5% Adjusted EPS* $8.15 - $8.35 $1.73 - $1.78 Other Modeling Items: FX Impact on Sales (a) ~1% ~2.5% Acquisition/Divestiture Impact on Sales ~0.5% ~1% Corporate/Un
Slide 12: IDEX Value Drivers
IDEX Value Drivers Differentiated 8020 operating model drives full business potential through simplification, focused resourcing and streamlined execution Focused on continuously evolving our portfolio toward high-growth, advantaged markets with secular tailwinds Balanced allocator of capital with s
Slide 13: Non-GAAP Reconciliations
Click Here to Edit Title Non-GAAP Reconciliations
Slide 14: Table 1: Reconciliations of the Change in Net Sales to Organic Sales
Click Here to Edit Title Table 1: Reconciliations of the Change in Net Sales to Organic Sales HST FMT FSDP IDEX For the Quarter Ended December 31, 2025 Change in net sales 9% 2% (3%) 4% Less: Net impact from acquisitions/divestitures(1) 2% —% —% 1% Impact from foreign currency(2) 2% 1% 2% 2% Change
Slide 15: Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin
Click Here to Edit Title Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (dollars in millions) For the Quarter Ended December 31, For the Year Ended December 31, 2025 2024 2025 2024 Gross profit $ 387.1 $ 367.1 $ 1,538.8 $ 1,445.2 Fair value inventory step-up charges —
Slide 16: Table 3: Reconciliations of Reported-to-Adjusted Net Income and Diluted EPS
Click Here to Edit Title Table 3: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts) For the Quarter Ended December 31, For the Year Ended December 31, 2025 2024 2025 2024 Reported net income attributab
Slide 17: Table 4: Reconciliations of Net Income to Adjusted EBITDA
Click Here to Edit Title Table 4: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions) For the Quarter Ended December 31, For the Year Ended December 31, 2025 2024 2025 2024 Reported net income $ 128.3 $ 123.2 $ 482.5 $ 504.6 Provision for income taxes 39.4 28.0 150.1 134.7 Interes
Slide 18: Table 5: Reconciliations of Cash Flows to Free Cash Flow
Click Here to Edit Title Table 5: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (dollars in millions) For the Quarter Ended December 31, For the Year Ended December 31, 2025 2024 2025 2024 Cash flows from operating activities $ 209.5 $ 172.6 $ 680.4 $ 668.1 Less: Capital